Globe Pulsed Field System for Treating Paroxysmal Atrial Fibrillation Symptoms
Tests the Globe Pulsed Field System in adults with symptomatic paroxysmal atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Evaluation of the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation
Key facts
- Where
- Bellevue and Jonesboro, United StatesSee the 2 sites
Where in United States
- Overlake HospitalBellevue, United StatesNo longer taking part
- Arrhythmia Research GroupJonesboro, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kardium Inc.
- Trial code
- NCT07714876
- Record updated
- 9 November 2026
- Original description
This study will evaluate the long-term safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal atrial fibrillation.Read full original descriptionShow less
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal Atrial Fibrillation - Post Approval Study
This study will evaluate the long-term safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal atrial fibrillation.
Inclusion: A diagnosis of recurrent symptomatic paroxysmal atrial fibrillation; Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III.
Exclusion: Any cardiac surgery within the previous six months; Prior left atrial ablation or surgical procedure; Atrial fibrillation secondary to a reversible cause or of non-cardiac origin; History of thromboembolic events within the past six months; Myocardial infarction (MI)/percutaneous coronary intervention (PCI) within the last three months; Left ventricular ejection fraction (LVEF) <35%; Persistent or long-standing persistent atrial fibrillation (continuous atrial fibrillation that is sustained >12 months); Presence of any pulmonary vein stents; Body mass index (BMI) >40 kg/m\^2; Anterior-posterior left atrial (LA) diameter >55mm.